Aimei Signs Non-Binding LOI to Merge With Hera Health Solutions
AFJK sits 75% above its 52-week low of $6.75.
Summary
Aimei Health Technology signed a non-binding letter of intent on November 14, 2026 to combine with Memphis-based drug-delivery company Hera Health Solutions, acquiring 100% of Hera's equity for shares of the combined public company. No valuation, exchange ratio or closing conditions were disclosed, and the SPAC's business combination deadline is December 6, 2026.
Key Events · M&A and Partnerships · AFJK
-
New SPAC Target: Hera Health Solutions
On November 14, 2026 Aimei signed a non-binding LOI to acquire 100% of Hera Health Solutions Inc.'s outstanding equity and equity equivalents in exchange for shares of the combined public company. Hera is a Memphis, Tennessee pharmaceutical technology company developing biodegradable nanofiber drug-delivery implants and patches.
-
No Deal Economics Disclosed
The LOI states no valuation, exchange ratio, minimum cash/trust condition or financing commitment. Aimei says it expects to announce additional details only upon execution of a definitive business combination agreement.
-
Non-Binding Except Exclusivity
The LOI binds the parties only on confidentiality, exclusivity and other customary provisions. Closing remains subject to definitive agreements, due diligence, regulatory and shareholder approvals and other customary conditions, with no assurance any deal is signed or consummated.
-
December 6, 2026 Deadline Looms
The combination must close before the current charter deadline of December 6, 2026, which Aimei reached by depositing $34,330.96 into trust for a one-month extension. A 12-month extension to December 6, 2027 was put to shareholders at a November 10, 2026 vote.
Analysis · AFJK · Real Estate & Construction
For Aimei, a SPAC whose prior deal collapsed and whose combination deadline has been pushed forward one month at a time — most recently to December 6, 2026 — signing a letter of intent with a new target is the difference between a viable deal path and liquidation. That is why this matters more than the document's thin terms suggest. The company also carries a going-concern warning and two Nasdaq deficiency notices for falling below minimum market value thresholds. The LOI is explicitly non-binding apart from confidentiality and exclusivity, discloses no valuation, no exchange ratio and no minimum trust condition, and still requires definitive agreements, due diligence, regulatory and shareholder approvals. The hard constraint is the calendar: a December 6, 2026 deadline against a process that has not yet produced a signed definitive agreement, and the company has already shown it needs shareholder approval for further extensions.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 48.3% of the 2133 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.28%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, AFJK was trading at $11.84 on NASDAQ in the Real Estate & Construction sector, with a market capitalization of approximately $37.5M. The 52-week trading range was $6.75 to $130.37. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.